Sulfiredoxin Redox-Sensitive Interaction with S100A4 and Non-Muscle Myosin IIA Regulates Cancer Cell Motility

被引:33
|
作者
Bowers, Robert R. [1 ]
Manevich, Yefim [1 ]
Townsend, Danyelle M. [2 ]
Tew, Kenneth D. [1 ]
机构
[1] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA
基金
美国国家卫生研究院;
关键词
CYSTEINE-SULFINIC ACID; S-GLUTATHIONYLATION; STRUCTURAL-CHANGES; SCAFFOLD PROTEINS; LUNG-CANCER; IN-VITRO; PEROXIREDOXIN; METASTASIS; MECHANISM; FAMILY;
D O I
10.1021/bi301006w
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sulfiredoxin (Srx) is a redox active protein that participates in the reduction of oxidized cysteine residues. Here we identify a novel function of Srx through its specific binding to S-glutathionylated S100A4 affecting its interaction with nonmuscle myosin (NMIIA), thereby modulating the effect of S100A4 on NMIIA function and impacting cell adhesion and migration. Srx forms a complex with S100A4 (and has stronger affinity for S-glutathionylated S100A4), regulates its activity, and mediates redox regulation of the interaction of S100A4 with NMIIA The consequence of this regulation is microfilament remodeling and altered cellular motility and adhesion. Srx-overexpressing cells had reduced levels of adhesion, decreased levels of Tyr(397)-phosphorylated focal adhesion kinase, and increased cell motility in wound healing assays. These results describe a novel redox-sensitive role for Srx in mediating complex protein interactions with plausible consequences for cancer cell motility.
引用
收藏
页码:7740 / 7754
页数:15
相关论文
共 46 条
  • [41] Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer
    C Blick
    A Ramachandran
    S Wigfield
    R McCormick
    A Jubb
    F M Buffa
    H Turley
    M A Knowles
    D Cranston
    J Catto
    A L Harris
    British Journal of Cancer, 2013, 109 : 50 - 59
  • [42] Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer
    Blick, C.
    Ramachandran, A.
    Wigfield, S.
    McCormick, R.
    Jubb, A.
    Buffa, F. M.
    Turley, H.
    Knowles, M. A.
    Cranston, D.
    Catto, J.
    Harris, A. L.
    BRITISH JOURNAL OF CANCER, 2013, 109 (01) : 50 - 59
  • [43] Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3
    Wu, Xu
    Zhang, Hui
    Jiang, Gang
    Peng, Minlian
    Li, Cheng
    Lu, Jiaxin
    Jiang, Shiyin
    Yang, Xiaoping
    Jiang, Yongliang
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2022, 210 (03): : 309 - 320
  • [44] Small interfering RNA targeting S100A4 sensitizes non-small-cell lung cancer cells (A549) to radiation treatment
    Qi, Ruixue
    Qiao, Tiankui
    Zhuang, Xibing
    ONCOTARGETS AND THERAPY, 2016, 9 : 3753 - 3762
  • [45] S100A4 alters mitochondrial metabolism to promote invasion and metastasis of non-small cell lung cancer cells through upregulation of NDUFS2
    Liu, Lili
    Qi, Lei
    Knifley, Teresa
    Piecoro, Dava W.
    Rychahou, Piotr
    Liu, Jinpeng
    Mitov, Mihail I.
    Martin, Jeremiah
    Wang, Chi
    Wu, Jianrong
    Weiss, Heidi L.
    Butterfield, D. Allan
    Evers, B. Mark
    O'Connor, Kathleen L.
    Chen, Min
    CANCER RESEARCH, 2019, 79 (13)
  • [46] S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide
    Stewart, Rachel L.
    Carpenter, Brittany L.
    West, Dava S.
    Knifley, Teresa
    Liu, Lili
    Wang, Chi
    Weiss, Heidi L.
    Gal, Tamas S.
    Durbin, Eric B.
    Arnold, Susanne M.
    O'Connor, Kathleen L.
    Chen, Min
    ONCOTARGET, 2016, 7 (23) : 34630 - 34642